The initiation of coverage by Evercore ISI Group with an In-Line rating and a price target of $22.5 for Agilon Health is likely to have a neutral impact on the stock price in the short term. The In-Line rating suggests that the stock is expected to perform similarly to the market, and the price target is not significantly different from the current stock price. The news is relevant and important for investors, but the neutral rating does not indicate a strong price movement in either direction.